PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.
IPO Year:
Exchange: NASDAQ
Website: pharmacyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2021 | Neutral | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of PharmaCyte Biotech with a rating of Neutral
8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)
DEFA14A - PharmaCyte Biotech, Inc. (0001157075) (Filer)
DEF 14A - PharmaCyte Biotech, Inc. (0001157075) (Filer)
8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)
S-8 - PharmaCyte Biotech, Inc. (0001157075) (Filer)
10-Q - PharmaCyte Biotech, Inc. (0001157075) (Filer)
10-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
NT 10-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FD
Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (NASDAQ:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company's first investment in externally developed technology, which it believes will provide significant additional shareholder value and serv
- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys' infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys' lead product candidate, FemBloc® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products,
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunities PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In the meantime, the Company is reviewing multiple potential opportunities that i
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company's common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest. The tender offer expired one minute after 11:59 p.m. on June 9, 2023, and was funded entirely through the Company's cash on hand. PharmaCyte CEO Josh Silverman commented, "Having completed the tender offer, we believe we are in a stronger position to optimize shareholder value. Our significant cash position of approximately $74 million following the
Jonathan Schechter and Robert Weinstein Join Oblong's Board of Directors Oblong, Inc. (NASDAQ:OBLG) ("Oblong" or the "Company"), the award-winning maker of multi-stream collaboration solutions, today appointed two new directors to its board. Jonathan Schechter, Partner, The Special Equities Group, and Robert Weinstein, Chief Financial Officer, Synaptogenix, Inc. have joined Oblong's board of directors. In addition, Jim Lusk and Matthew Blumberg have retired from the Oblong board. "We're delighted to welcome Jonathan and Robert to the Oblong board of directors," said Pete Holst, President and CEO. "Both individuals bring a wealth of knowledge in mergers and acquisitions, digital transfor
Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it has completed a private placement financing of convertible redeemable preferred stock and warrants from existing investors, raising gross proceeds of approximately $35 million in a private placement financing of convertible redeemable preferred stock and warrants from existing investors. Tender Offer The Company intends to commence th
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that its Board of Directors has authorized a second share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock. This second share repurchase authorization is effective immediately for a two-year period. PharmaCyte expects to fund the program with its available cash. The Company enacted a similar program in June 2022. PharmaCyte's CEO Josh Silverman commented, "Based
LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box for potential development of cellular therapies for cancer, diabetes and malignant ascites, announces today that its Board of Directors has empowered its Business Review Committee to evaluate opportunities to realize optimal shareholder value. In addition, CEO Kenneth L. Waggoner has stepped down from the position as CEO effective October 6, 2022. The Board has since appointed Joshua N. Silverman, a member of the Board, as interim CEO. Mr. Silverman commented, "On